A team of SHP faculty and researchers, together with Stanford Medicine graduate and medical students and in collaboration with colleagues at CIDE in Mexico, have launched a modeling framework to investigate the epidemiology of COVID-19 and to support pro-active resource planning and policy evaluations for diverse populations and geographies — including California, Mexico and India.

The Stanford-CIDE Coronavirus Simulation Model — or SC-COSMO — incorporates realistic demography and patterns of contacts sufficient for transmission of the virus that has infected more than 2 million people worldwide and claimed more than 125,600 lives, according to the widely used Johns Hopkins COVID-19 map which is updated several times a day.

The SC-COSMO model also incorporates non-pharmaceutical interventions, such as social distancing, timing and effects on reductions in contacts which may differ by demography.

Jeremy Goldhaber-Fiebert, an associate professor of medicine at Stanford Health Policy, is the principal investigator of the project, along with Fernando Alarid-Escudero, an assistant professor at the Center for Research and Teaching in Economics (CIDE) in Mexico and Jason Andrews, an assistant professor of medicine (infectious diseases) at Stanford Medicine. Other SHP faculty among the 20 investigators and staff members who are working on the project are Joshua Salomon and David Studdert, both professors of medicine.

The SC-COSMO team is a multi-disciplinary, multi-institutional team including expertise and experience in infectious disease, epidemiology, mathematical modeling and simulation, statistics, decision science, health policy, health law and health economics.

“As COVID-19 transmission occurs throughout the world’s diverse populations, it is critical to efficiently model and forecast its future spread between and within these populations and to appropriately reflect uncertainty in modeled outcomes,” Goldhaber-Fiebert said. “Doing so supports timely resource planning and decision making between potentially appropriate and effective interventions that balance the trade-offs they embody.”

The team is currently working on three projects:

1. The researchers are providing California with county-level COVID-19 estimates for such things as the number of infections, detected cases and projections of future needs for hospital and ICU beds, personal protective equipment (PPE) and ventilators.
2. The project is working on potential strategies to mitigate the COVID-19 pandemic in Mexico by focusing on three specific objectives: collecting, synthesizing and openly sharing the most relevant and useful data; accelerating the development of the SC-COSMO model and its adaptation to the Mexican situation; and identifying a set of mitigation strategies, comparing the health and economic consequences in the population in the medium and long term.
3. They are developing forecast models of the COVID-19 epidemic in India with the Wadhwani Institute of Artificial Intelligence and its Indian government partners, providing a rapid response to urgent needs for planning and resource allocation.

Genetic mapping has led scientists to a better understanding of human disease and how to fight ailments like diabetes, mental illness and cancer.

But the information they have to work with is limited, drawing mostly from the DNA of people with European bloodlines. When it comes to figuring out how genetic disorders affect groups who don’t share that ancestry or have only trace amounts of it in their family histories, researchers are often at a loss.

Andres Moreno is changing that. Thanks to the $100,000 he is receiving as this year’s recipient of the George Rosenkranz Prize for Health Care Research in Developing Countries, the Stanford researcher will analyze the DNA of indigenous groups and cosmopolitan populations living in Mexico, South America and the Caribbean.

The data he gathers will lay the groundwork for scientists interested in knowing how genetic diseases take hold and manifest themselves among Latin Americans – one of the most underrepresented populations in the field of genetics.

“We can’t start talking about how to deliver personalized medicine in Latin America because we still have much to learn about their genetic makeup at the population level,” said Moreno, a research associate at School of Medicine’s genetics department.

“We need to draw the genetic map that will allow us to better understand the genetic basis of multiple conditions that lead to major health problems in Latin America,” he said.

Scientists have found numerous genetic variants linked to complex traits among people with European backgrounds, and that connection has allowed doctors to better treat and prevent diseases in that group.

But without a rich database built on the DNA of people whose family trees are rooted in Latin America, researchers have yet to find the genetic key to explain why descendants of region’s indigenous populations are predisposed to particular conditions.

Obesity, for example, is more prevalent in Mexico than in other parts of the world, Moreno said.

“We need to find population-specific gene variants that don’t exist anywhere else but locally,” he said. “Then we can maybe find the gene behind obesity there.”

Other conditions may be addressed by studying locally adapted populations, such as those living at high altitude in the Andes where pregnant women have a five-fold higher rate of maternal hypertension than the native population.

“We are trying to identify the genetic variants underlying the mechanisms for this protection, which may help to design preventive and therapeutic measures worldwide,” Moreno said.

Stanford’s Center for Health Policy, a center of the university’s Freeman Spogli Institute for International Studies, administers the Rosenkranz award that will fund Moreno’s work. The prize was created in 2007 to foster the research of a young Stanford scholar committed to improving health care in developing countries and reducing health disparities across the globe.

The first recipient was Eran Bendavid, an assistant professor of medicine and a CHP associate.

“We believe Andres’ work will deepen our understanding of the genetics of disease across populations, and we are delighted to recognize his important scientific contributions,” said Douglas Owens, director of the Center for Health Policy, the Henry J. Kaiser, Jr. Professor in the School of Medicine and an FSI senior fellow.

The Rosenkranz prize was established by the friends and family of Dr. George Rosenkranz, the scientist who helped first synthesize Cortizone in Mexico in 1951.

Rosenkranz, who lives in Menlo Park, also synthesized the active ingredient for the first oral birth control and served as a CEO of Syntex, a Mexican pharmaceutical company.

In addition to Owens, members of the award selection committee included: Donald Kennedy, president emeritus of Stanford; Rosamond Naylor, the William Wrigley Senior Fellow at FSI and Stanford’s Woods Institute for the Environment; Paul Yock, the Martha Meier Weiland Professor in the medical school; and Michele Barry, the medical school’s senior associate dean of global health and director of the Center for Innovation in Global Health.

Young Stanford researchers focusing on improving health care access in developing countries are eligible for the Dr. George Rosenkranz Prize.

The $100,000 award is given to a non-tenured professor, post-doctoral student or research associate during a two-year period. The deadline to apply is May 11. The recipient will be announced in early June

Rosenkranz, who helped first synthesize Cortisone in 1951 and went on to synthesize progestin  – the active ingredient for the first oral birth control – dedicated his career to improving health care access around the world. Born in Hungary in 1916, the chemist started his career in Mexico and helped establish the Mexican National Institute for Genomic Medicine. He lives with his wife in Menlo Park.

The award is being funded by the Rosenkranz family and administered by Stanford Health Policy, a center within the Freeman Spogli Institute for International Studies and the Center for Primary Care and Outcomes Research. It also is designed to give its recipients access to a network that will help them develop their careers.

Eran Bendavid, a SHP affiliate and Stanford Medical School instructor, received the first award in 2010 to support his analysis of whether money going to HIV and malaria programs in sub-Saharan Africa has improved the overall health of children and their mothers.

More application information is available at http://healthpolicy.stanford.edu/fellowships/rosenkranz_prize.